Why the study?
Nuclear medicine has shown promise in diagnosing cancer therapy-related cardiomyopathies, heart failure, and peri- and myocarditis, but specific suggestions for applying available nuclear imaging techniques were needed.
Population
Patients undergoing cancer therapy at risk for or presenting with cardiotoxicity
Design
Guideline
Authors
Loading...
Supports integration of ERNA/SPECT/PET into cardio-oncology surveillance; extends consensus with standardized EANM guidance.
This EANM position paper outlines the role of nuclear medicine imaging, including ERNA and MPI, as valuable tools for assessing and monitoring cancer therapy-related cardiotoxicity.
Totzeck et al. (2022) conducted a review in Cancer therapy-related cardiotoxicity. Nuclear medicine imaging was evaluated. Nuclear medicine imaging techniques, including ERNA, SPECT, and PET, offer valuable and highly reproducible methods for the early detection and monitoring of cancer therapy-related cardiotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: